In PC-3 prostate cancer cells, MYC expression was shown to be more sensitive to PPRHs, resulting in a more pronounced downregulation compared to KRAS, whereas the reverse was true in KRAS-mutant and -dependent AsPc-1 pancreatic cancer cells. The gene discussed is KRAS; the disease is pancreatic neoplasm.